COMMUNIQUÉS West-GlobeNewswire

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
19/03/2024
BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and [...]
Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance
19/03/2024
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study of optical genome mapping (OGM) in hereditary breast and ovarian cancer (HBOC) syndrome [...]
Rejuvenation Medical Group of Canada uses MedMatrix AI Reporter to Streamline Reporting and Improve Operations
19/03/2024
VANCOUVER, British Columbia, March 19, 2024 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (the “Company” or “MedBright”) (CSE:MBAI, OTCQB:MBAIF, FSE:1V7) today announced Rejuvenation medical group is using the [...]
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024
19/03/2024
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the [...]
Spectral AI Announces Receipt of $1 Million of Financing for Spectral IP, Inc., its Intellectual Property Subsidiary Focused on the Broader Artificial Intelligence Ecosystem
19/03/2024
DALLAS, March 19, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]
Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
19/03/2024
Four healthy subjects dosed with RECCE ® 327 at 3,000mg over 20 minutes Data received from this cohort will support preparations for a Phase II trial SYDNEY, Australia, March 19, 2024 (GLOBE NEWSWIRE) -- Recce [...]
Cytek® Biosciences Names William McCombe Chief Financial Officer
19/03/2024
Experienced executive with extensive background as CFO for global corporations across dynamic sectors Cytek reaffirms 2024 outlook FREMONT, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: [...]
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024
19/03/2024
RESEARCH TRIANGLE PARK, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release [...]
Unauthorized Access to Employee Mobile Devices Leads to More Than Half of Organizations Experiencing a Data Breach, New Report Finds
19/03/2024
Research conducted by Imprivata and Ponemon Institute finds 28% of IT and IT security practitioners say their organizations can secure devices and access to data, while less than half cite satisfaction with the access [...]
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
19/03/2024
56% of Participants on Paltusotine Achieved IGF-1 ≤1.0 xULN vs. 5% on Placebo (p<0.0001) Paltusotine was Generally Well-tolerated with No Serious Adverse Events Positive Topline Results Support Planned NDA Submission [...]
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024
19/03/2024
MELBOURNE, Australia and PRINCETON, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly [...]
Leading in health technology innovation: Philips one of the top patent applicants at European Patent Office
19/03/2024
March 19, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it is one of the leading patent applicants at the European Patent Office (EPO [...]
XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial
19/03/2024
CALGARY, Alberta, March 19, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused [...]
Engage with Pluri's Talent: Exciting Conference Appearances Ahead
19/03/2024
HAIFA, Israel, March 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote global wellbeing and [...]
Mendus to present NK cell program progress at the Innate Killer Summit
19/03/2024
Press Release Stockholm, Sweden, March 19, 2024 Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces that it will present the progress of its [...]
IBA signs contract to install a Be-Efficient irradiation solution in Germany
19/03/2024
Louvain-la-Neuve, Belgium, March 19, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial irradiation, announced [...]
IBA signe un contrat pour l'installation d'une solution d'irradiation Be-Efficient en Allemagne
19/03/2024
Louvain-la-Neuve, Belgique, le 19 mars 2024 - IBA (Ion Beam Applications S.A.), le leader mondial des technologies d’accélération de particules et des solutions d'irradiation industrielle par faisceau d'électrons et [...]
AstriVax Rounds Out Executive Team with Chief Business Officer (CBO) Dr. Gregory Fanning
19/03/2024
Dr. Fanning brings a wealth of experience in creating infectious disease pipelines by internal R&D and licensing As the CBO of AstriVax, he will lead the company’s business development, including partnerships, [...]
ObsEva Announces Update on Board of Directors
19/03/2024
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s [...]

Pages